Billionaire David Tepper Sold Every Single Share of UnitedHealth in Q2. Here's Whether He Made a Costly Mistake.

I think David Tepper made a mistake selling UnitedHealth Group (NYSE: UNH), and not a small mistake either. When I look at what this company is doing and where healthcare is headed, I would rather buy the stock than walk away.

For context, here's what happened: Tepper is a billionaire hedge fund manager, the founder and president of Appaloosa Management. Tepper didn't trim his stake in UnitedHealth. He sold every share, about 90,000 in total, refocusing his portfolio toward artificial intelligence (AI) with purchases of Amazon (NASDAQ: AMZN), Micron (NASDAQ: MU), and Taiwan Semiconductor (NYSE: TSM), which now account for nearly 40% of his fund. That tells me his move was about concentrating on a narrower theme, not about UnitedHealth losing its edge. In earlier filings, UnitedHealth ranked among his top positions, accounting for more than 10% of the portfolio, indicating he once saw it as a core holding.

Is UnitedHealth a sell?

So what changed? The obvious worry is medical cost pressure, especially from GLP‑1 weight loss drugs and broader inflation in care. UnitedHealth's Q2 2026 numbers show medical costs of $75.36 billion and a medical care ratio of 86.7%, down from 89.4% a year earlier but still above the mid-80s range the company had framed as its target (lower is better). Some investors see that as a sign that margins will stay under pressure and that insurers will never fully catch up to medical care's rising cost curve. Tepper may have decided that the headache was not worth the trouble.

Image source: Getty Images.

When I dig into the details, I see something different. UnitedHealth is not sitting still and hoping costs fall. It's reshaping how care is delivered across its UnitedHealthcare insurance arm and Optum pharmacy management services. On GLP‑1 drugs, the company has drawn a clear line, covering them for diabetes and cardiovascular risk under tight medical necessity rules and restricting coverage for weight loss alone. It has launched programs like Total Weight Support to combine medication with coaching and digital tools, which gives it a way to manage outcomes rather than paying for pills without structure. That kind of strategy matters when drug costs can top $1,000 per member each month.

At the same time, UnitedHealth is attacking administrative costs, which is where a lot of margin lives. Management plans to invest about $1.5 to $1.6 billion in AI in 2026, including a generative AI platform aimed at automating claims and back office work. Optum Rx has already used AI to cut call center volume by 25%, trim prior authorization times from hours to less than 30 seconds, and reduce denials and appeals by large double-digit percentages. Optum Health is rolling out ambient listening for doctors, with a target of 70% of employed providers this year and 90% by year's end, which saves clinical time and reduces burnout. Those changes don't show up in one quarter, but they change the unit economics of the business over time.

UnitedHealth's latest results hint at that shift. Operating margin rose from 4.6% to 7.1% year over year, aided by a lower medical care ratio and improved cost management, even as underlying trends remained elevated. Membership remains strong, and the mix continues to tilt toward Optum services, which carry higher margins than pure insurance. The company's forecast still calls for double-digit percentage gains in adjusted earnings for 2026, supported by a balance of pricing, care management, and productivity gains.

UnitedHealth is adapting and not falling behind

To me, all this looks like a franchise adapting to a changing healthcare landscape, not one losing control. GLP‑1 drugs will remain a challenge, but they also reduce complications from diabetes and cardiovascular disease, which, over time, can lower hospital costs borne by insurers. AI and workflow changes will take friction out of claims and prior authorization, which helps offset rising clinical spending. UnitedHealth sits at the intersection of those trends, with scale and data that smaller players can't match.

So should investors follow Tepper out of the stock? I don't think so. If your goal is to bet only on AI chips or high growth stocks, you won't find that profile here. If your goal is to own a company that touches tens of millions of patients, runs one of the most advanced health services platforms in the country, and has a clear plan to use technology to manage cost and experience, UnitedHealth still belongs in a long-term portfolio.

Micah Zimmerman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, Micron Technology, and Taiwan Semiconductor Manufacturing. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.